ARTV Artiva Biotherapeutics, Inc. Insider Trading

10% Owner GC Corp buys 1,432,291 shares ($16.5M) at $11.52 amid 47.6% decline from 52-week high

GC Corp, a 10% owner at Artiva Biotherapeutics, executed 2 separate purchases totaling 1,432,291 shares (1.43M shares) for $16,499,992.32 ($16.5M) at a blended average price of $11.52, expanding holdings from 175,443 to 1,607,734 shares (+816.4%). The transaction occurs as the stock trades at $7.61, representing a -47.6% decline from the 52-week high of $14.53 and a -16.1% drop over the prior 30 days. The company's fundamentals are strained: latest-quarter revenue totaled $251,000.00 ($251.0K), annual revenue contracted by -100.0%, and net income was negative $-23,516,000.00 ($-23.5M) over the most recent full fiscal year. GC Corp's prior buy activity at this same ticker (2 prior trades on 2024-07-22) both exhibited +1.4% 90-day returns, suggesting a pattern of well-timed entry points at this specific security, though the current substantially lower price level and accelerated cash burn relative to declining revenue represent material context shifts that warrant investor attention.

Ra Capital Management increases stake in ARTV by 75% with ~$75M open-market purchase; first buy at this company in 36 months.

Ra Capital Management, a board director and major shareholder, deployed approximately $75 million to acquire a substantial block of Artiva shares, expanding its indirect stake by more than 75 percent—the largest single acquisition in the fund's 36-month filing history at this company. The purchase occurred while the stock trades well below its 52-week high and follows a dramatic rally over the prior quarter, yet the company remains unprofitable with revenues declining sharply and significant annual net losses. Notably, this represents Ra Capital's first open-market purchase of ARTV shares on record, despite the fund's extensive trading activity across other holdings over the past three years—suggesting a deliberate shift toward this particular investment after a period of inactivity. The timing and scale of the buy are notable given the stock's weak fundamentals, though Ra Capital's prior open-market purchases across its broader portfolio have demonstrated a strong track record of capturing upside gains within 90 days.